Gilead Sciences, Inc. (GILD) News

Gilead Sciences delivered robust first-quarter results characterized by significant growth in its core virology business and rapid uptake of newly launched therapies. The financial outperformance provides management with the flexibility to absorb major strategic acquisitions while upgrading top-line expectations for the year.

A resilient core business, fueled by a dominant HIV franchise and rapidly expanding liver portfolio, continues to propel financial outperformance despite significant policy-driven pricing obstacles. The company remains highly focused on accelerating multiple major commercial launches in the upcoming year, capitalizing on its strongest clinical pipeline in decades.